SCHEMBL2203076

SCHEMBL2203076

CCc1nn(-c2cccc(/C=C/c3ccc(Cl)cc3)c2)c(CC)c1C(=O)N1CCCN(CCO)CC1

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 4/20 0.36
TP53 P04637 2/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
ALPL P05186 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
PYGL P06737 3/20 0.34
HTR1A P08908 1/20 0.34
HTR7 P34969 1/20 0.34
HTR2A P28223 1/20 0.34
LMNA P02545 2/20 0.33
USP14 P54578 1/20 0.33
TSHR P16473 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2203081 1.00 PARP1 (0.36) PARP1TP53PTGDR2ALPLKDM4E
SCHEMBL2199024 0.88 PARP1 (0.35) PARP1ALPLALDH1A1PYGLHTR1A
SCHEMBL2199019 0.88 PARP1 (0.35) PARP1ALPLALDH1A1PYGLHTR1A
SCHEMBL2199839 0.85 KMT2A (0.44) PARP1TP53ALPLKDM4EALDH1A1
SCHEMBL2199832 0.85 KMT2A (0.44) PARP1TP53ALPLKDM4EALDH1A1
SCHEMBL2200736 0.84 CACNA2D1 (0.38) TP53PTGDR2KDM4EALDH1A1
SCHEMBL2200740 0.84 CACNA2D1 (0.38) TP53PTGDR2KDM4EALDH1A1
SCHEMBL2202799 0.82 L3MBTL3 (0.41) PTGDR2
SCHEMBL2202806 0.82 L3MBTL3 (0.41) PTGDR2
SCHEMBL2202671 0.81 KMT2A (0.46) TP53ALPLKDM4EALDH1A1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
EP-2182953-A2 NEW PYRAZOL DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-05-12 EP disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 WO disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 PARP1 2046/4885TP53 3028/4885PTGDR2 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.